DiCE Molecules Appoints Industry Veteran Richard Scheller To Board Of Directors
SAN FRANCISCO--(BUSINESS WIRE)--DiCE Molecules, a privately held company developing a next generation approach to small molecule drug discovery, today announced the appointment of Richard Scheller, Ph.D., chief scientific officer and head of therapeutics at 23andMe, to its board of directors. Dr. Scheller brings to DiCE nearly 20 years of leadership in drug discovery research and development.